The use of vasopressin receptor antagonists in hyponatremia

Bibliography

• Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006;119(7 Suppl 1):S30-5
   PubMedGoogle Scholar
• Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 2003;337(1-2):169-72
   PubMed Web of Science ®Google Scholar
• Bennani SL, Abouqal R, Zeggwagh AA, Incidence, causes and prognostic factors of hyponatremia in intensive care. Rev Med Interne 2003;24:224-9
   PubMed Web of Science ®Google Scholar
• Wald R, Jaber BL, Price LL, Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010;170(3):294-302
   PubMed Web of Science ®Google Scholar
• Sajadieh A, Binici Z, Mouridsen MR, Mild hyponatremia carries a poor prognosis in community subjects. Am J Med 2009;122(7):679-86
   PubMed Web of Science ®Google Scholar
• Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009;122(9):857-65
   PubMed Web of Science ®Google Scholar
• Renneboog B, Musch W, Vandemergel X, Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006;119(1):, 71.e1-71.e8
   PubMedGoogle Scholar
• Gankam Kengne F, Andres C, Sattar L, Mild hyponatremia and risk of fracture in the ambulatory elderly. QJM 2008;101:583-8
   PubMed Web of Science ®Google Scholar
• Kinsella S, Moran S, Sullivan MO, Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol 2010;5:275-80
   PubMed Web of Science ®Google Scholar
• Sandhu HS, Gilles E, DeVita MV, Hyponatremia associated with large bone fracture in elderly patients. Int Urol Nephrol 2009;41:733-7
   PubMed Web of Science ®Google Scholar
• Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 2006;17(7):1820-32
   PubMed Web of Science ®Google Scholar
• Ellis SJ. Severe hyponatraemia: complications and treatment. QJM 1995;88(12):905-9
   PubMed Web of Science ®Google Scholar
• Sterns RH, Nigwekar SU, Hix JK. The treatment of hyponatremia. Semin Nephrol 2009;29(3):282-99
   PubMed Web of Science ®Google Scholar
• Roh JH, Kim JH, Oh K, Cortical laminar necrosis caused by rapidly corrected hyponatremia. J Neuroimaging 2009;19(2):185-7
   PubMed Web of Science ®Google Scholar
• Odier C, Nguyen DK, Panisset M. Central pontine and extrapontine myelinolysis: from epileptic and other manifestations to cognitive prognosis. J Neurol 2010;257(7):1176-80
   PubMed Web of Science ®Google Scholar
• Sterns RH, Hix JK, Silver S. Treatment of hyponatremia. Curr Opin Nephrol Hypertens 2010;19(5):493-8
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Goldsmith SR, Greenberg A, Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(11 Suppl 1):S1-21
   PubMed Web of Science ®Google Scholar
• Berl T, Rastegar A. A patient with severe hyponatremia and hypokalemia: osmotic demyelination following potassium repletion. Am J Kidney Dis 2010;55(4):742-8
   PubMed Web of Science ®Google Scholar
• Karp BI, Laureno R. Pontine and extrapontine myelinolysis: a neurologic disorder following rapid correction of hyponatremia. Medicine 1993;72:359-73
   PubMed Web of Science ®Google Scholar
• Sterns RH, Hix JK. Overcorrection of hyponatremia is a medical emergency. Kidney Int 2009;76(6):587-9
   PubMed Web of Science ®Google Scholar
• Perianayagam A, Sterns RH, Silver SM, DDAVP is effective in preventing and reversing inadvertent overcorrection of hyponatremia. Clin J Am Soc Nephrol 2008;3(2):331-6
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Barsony J, Sugimura Y, Hyponatremia-induced osteoporosis. J Bone Miner Res 2010;25:554-63
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gross P, Gheorghiade M, Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355(20):2099-112
   PubMed Web of Science ®Google Scholar
• Schrier RW. Does ‘asymptomatic hyponatremia’ exist? Nat Rev Nephrol 2010;6:185
   PubMed Web of Science ®Google Scholar
• Rosner MH. Severe hyponatremia associated with the combined use of thiazide diuretics and selective serotonin reuptake inhibitors. Am J Med Sci 2004;327(2):109-11
   PubMed Web of Science ®Google Scholar
• Cherrill DA, Stote RM, Birge JR, Singer I. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med 1975;83:654-6
   PubMed Web of Science ®Google Scholar
• Dousa TP, Wilson DM. Effects of demethylchlortetracycline on cellular action of antidiuretic hormone in vitro. Kidney Int 1974;5:279-84
   PubMed Web of Science ®Google Scholar
• Miller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 1980;243:2513-15
   PubMed Web of Science ®Google Scholar
• Zegers de Beyl D, Naeije R, de Troyer A. Demeclocycline treatment of water retention in congestive heart failure. BMJ 1978;1:760
   PubMed Web of Science ®Google Scholar
• Decaux G, Mols P, Cauchi P, Delwiche F. Use of urea for treatment of water retention in hyponatraemic cirrhosis with ascites resistant to diuretics. BMJ (Clin Res Ed) 1985;290:1782-3
   PubMed Web of Science ®Google Scholar
• Decaux G, Andres C, Gankam Kengne F, Soupart A. Treatment of euvolemic hyponatremia in the intensive care unit by urea. Crit Care 2010;14(5):R184
   PubMedGoogle Scholar
• Decaux G, Waterlot Y, Genette F, Inappropriate secretion of antidiuretic hormone treated with frusemide. Br Med J (Clin Res Ed) 1982;285(6335):89-90
   PubMed Web of Science ®Google Scholar
• Forrest JN Jr, Cox M, Hong C, Superiority of demeclocycline over lithium in the treatment of chronic syndrome of inappropriate secretion of antidiuretic hormone. N Engl J Med 1978;298:173-7
   PubMed Web of Science ®Google Scholar
• Velez JC, Dopson SJ, Sanders DS, Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant 2010;25(5):1524-31
   PubMed Web of Science ®Google Scholar
• Ghali JK, Koren MJ, Tylor JR, Conivaptan study group. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006;91:2145-52
   PubMed Web of Science ®Google Scholar
• Li-Ng M, Verbalis JG. Conivaptan: evidence supporting its therapeutic use in hyponatremia. Core Evid 2010;4:83-92
   PubMedGoogle Scholar
• Berl T, Quittnat-Pelletier F, Verbalis JG, SALTWATER Investigators. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21(4):705-12
   PubMedGoogle Scholar
• Greenberg A, Lehrich RW. Treatment of chronic hyponatremia: now we know how, but do we know when or if? J Am Soc Nephrol 2010;21(4):552-5
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Adler S, Schrier RW, Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol in press
   Google Scholar
• Martin PY, Abraham WT, Leiming X, Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999;10:2165-70
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Abraham WT, Albert NM, OPTIMIZE-HF Investigators and Coordinators. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007;28(8):980-8
   PubMedGoogle Scholar
• Lee DS, Austin PC, Rouleau JL, Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290(19):2581-7
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005;46:1785-91
   PubMed Web of Science ®Google Scholar
• Thibonnier M, Conarty DM, Preston JA, Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998;449:251-76
   PubMed Web of Science ®Google Scholar
• Abraham WT, Aranda JM, Boehmer JP, Rationale and Design of the Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation (THE BALANCE) Study. Clin Transl Sci 2010;3(5):249-53
   PubMed Web of Science ®Google Scholar
• Heuman DM, Abou-assi SG, Habib A, Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at risk for early death. Hepatology 2004;40:802-10
   PubMed Web of Science ®Google Scholar
• Okita K, Sakaida I, Okada M, A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterology 2010;45(9):979-87
   Google Scholar
• O'Leary JG, Davis GL. Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transpl 2009;15(10):1325-9
   PubMed Web of Science ®Google Scholar
• Wong F, Gines P, Watson H, Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 2010;53(2):283-90
   PubMed Web of Science ®Google Scholar
• Veeraveedu PT, Palaniyandi SS, Yamaguchi K, Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents. Drug Discov Today 2010;15(19-20):826-41
   Google Scholar